Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

  • STATUS
    Not Recruiting
  • participants needed
    124
  • sponsor
    CSL Behring
Updated on 2 March 2021
pneumonia
FIO2
pao2
covid-19
pao2/fio2 ratio
SARS
chest ct
oximetry
coronavirus infection

Summary

This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)

Details
Condition Coronavirus Disease 2019
Treatment Placebo, Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
Clinical Study IdentifierNCT04409509
SponsorCSL Behring
Last Modified on2 March 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note